Abstract
Pharmacologic approaches have emerged as alternatives to radical surgery for the treatment of aggressive central giant cell lesions (CGCL). We report three cases of CGCL managed with denosumab. Two of the patients were female adults presenting symptomatic lesions in maxilla. They received 120 mg subcutaneous denosumab monthly for 6 and 12 months (2 extra doses in the first month). The other was a 16-year-old male patient with Noonan syndrome, previously treated with calcitonin, who had mandibular and maxillary lesions. He received 60 mg denosumab for 6 months, followed by 30-mg doses for the next 2 months. No relevant adverse events were reported. After denosoumab therapy, all patients showed lesion calcification and significant recovery of the oral mucosa; however, little reduction in swelling was seen. Complementary recontouring surgery and curettage of the remaining lesion were proposed for all patients. Both female patients already undergone surgery, showing no recurrence at 3-year and 6-month follow-up.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
